HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
about
Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationValidation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B*58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions.Optimizing current treatment of gout.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity.
P2860
Q26800964-3D57D2C2-BE99-4C72-B1DA-D4662526B2D2Q28076600-E7852D5D-2494-4990-B3AA-5E23F289629BQ37404888-5DB618BD-45CF-42C3-93C8-ACAED0C337E2Q38194896-35435D46-3496-4F65-9F21-26C97C02B073Q38391340-817452D4-CB00-4D0E-B8A9-81ECC33C40A8Q39132630-6528497D-1569-4E55-9BFB-B0FEF5F24C95Q53135190-75470C84-AC2F-4DA9-B370-F32CABE71DF3
P2860
HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
@en
type
label
HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
@en
prefLabel
HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
@en
P2860
P356
P1476
HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
@en
P2093
Siaw Ing Yeo
P2860
P304
P356
10.1111/1756-185X.12050
P577
2013-04-26T00:00:00Z